Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Ownership
|
Insiders
Bullboard - Stock Discussion Forum
Revive Therapeutics Ltd
C.RVV
Alternate Symbol(s):
RVVTF
Healthcare
Biotechnology
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for infectious diseases and medical countermeasures. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro...
diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. The Company is also advancing the development of Psilocybin and molecular hydrogen therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (CSE:RVV)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(28)
•••
cool888
X
Post by
cool888
on Nov 30, 2022 6:14pm
Revive Announces Offering of Up to $5 Million !
https://ca.finance.yahoo.com/news/revive-therapeutics-ltd-announces-offering-224300276.html
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 30, 2022 5:43pm
New Press Release - Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) is pleased to announce that it is arranging a private placement of a minimum of $3 million and up to $5 million of units (each, a “Unit”), at a price of $0.15 per Unit; (the...
read article.
(28)
•••
cool888
X
Post by
cool888
on Nov 30, 2022 4:24pm
FDA pulls U.S. authorization for Eli Lilly's COVID drug !
Thought it may interest you ... https://www.nasdaq.com/articles/fda-pulls-u.s.-authorization-for-eli-lillys-covid-drug-bebtelovimab
(145)
•••
CrazyProphet
X
Comment by
CrazyProphet
on Nov 29, 2022 1:13am
RE:Markets 🤔 The worst performing market in
Posted wrong board my bad !
(145)
•••
CrazyProphet
X
Post by
CrazyProphet
on Nov 28, 2022 9:49pm
Markets 🤔 The worst performing market in
the western world has been the TSXV over the last 12 months off 40+ % so there is plenty of company swimming below surface. I remember buying Rupert Resources down low same BS as it dropped as low as
...more
(145)
•••
CrazyProphet
X
Post by
CrazyProphet
on Nov 28, 2022 10:15am
When this thing pops going to be a
lot of cry babies saying they should have bought at this price
(5)
•••
1ottrunner
X
Post by
1ottrunner
on Nov 24, 2022 11:02am
Let's see, mid-December + 75 days, carry the 1, divide by
That could be as far out as 90 days! MF has to put xmas presents under the tree, buy his New year cigars, he will need YOUR money! Are you still stockpiling fireworks Cool?
(28)
•••
cool888
X
Post by
cool888
on Nov 24, 2022 9:27am
$RVV $RVVTF - Update !
https://ca.finance.yahoo.com/news/revive-therapeutics-announces-type-c-141800286.html
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 24, 2022 9:18am
New Press Release - Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
TORONTO, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it will...
read article.
(22)
•••
hk1966
X
Comment by
hk1966
on Nov 23, 2022 12:38pm
RE:RE:$RVV Announces FDA Recommendation for Type C Meeting
C U down at a dime slick
(7)
•••
90guppy
X
Comment by
90guppy
on Nov 23, 2022 10:03am
RE:$RVV Announces FDA Recommendation for Type C Meeting
Mgt should buy at the market to show confidence, if they believe in bucillamine as much as the super longs here, MFrank and others should buy at market to show to longs their convictions.
(31)
•••
TheTerminator1
X
Post by
TheTerminator1
on Nov 22, 2022 11:29am
Bravo :)
EOM
(5)
•••
1ottrunner
X
Post by
1ottrunner
on Nov 22, 2022 10:38am
Did MF say he wouldn't seek financing?
I've been busy elsewhere so it escapes me. The meeting request will take RVV deep into the new year. That makes for a lean xmas for MF and his golf buddies. If the company needs to hit the
...more
(5)
•••
1ottrunner
X
Comment by
1ottrunner
on Nov 22, 2022 10:33am
RE:$RVV Announces FDA Recommendation for Type C Meeting
That adds 75 days to the docket.
(28)
•••
cool888
X
Post by
cool888
on Nov 22, 2022 10:10am
$RVV Announces FDA Recommendation for Type C Meeting
#Bucillamine https://ca.finance.yahoo.com/news/revive-therapeutics-announces-fda-recommendation-142000793.html
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
Silver North Intersects 13.15 m Averaging 818 g/t Silver and 1.39 g/t Gold at the Haldane Property